Summary
Merck & Co., Inc. (MRK) has filed an 8-K report on April 24, 2025, to disclose its financial results for the first quarter of 2025. The filing incorporates by reference a press release (Exhibit 99.1) issued on the same date, detailing the company's performance, along with supplemental financial information (Exhibit 99.2). Investors should refer to the attached press release and supplemental information for comprehensive details on revenue, earnings per share, product sales, and any forward-looking guidance provided by Merck. This 8-K serves as the official notification of these results, enabling investors to assess the company's operational and financial condition as of and for the period ending April 23, 2025.
Key Highlights
- 1Merck & Co., Inc. (MRK) reported its first quarter 2025 financial results on April 24, 2025.
- 2The 8-K filing incorporates by reference a detailed earnings press release (Exhibit 99.1).
- 3Supplemental financial information not included in the press release is also provided as Exhibit 99.2.
- 4The information pertains to the company's performance as of April 23, 2025.
- 5Investors are directed to the attached exhibits for specific financial data and operational highlights.
- 6This filing does not constitute a new debt or equity issuance.
- 7The company has not elected to opt-out of the extended transition period for new or revised accounting standards.